95 related articles for article (PubMed ID: 22401981)
1. Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort.
Markkula A; Hietala M; Henningson M; Ingvar C; Rose C; Jernström H
Cancer Prev Res (Phila); 2012 May; 5(5):735-45. PubMed ID: 22401981
[TBL] [Abstract][Full Text] [Related]
2. Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort.
Markkula A; Bromée A; Henningson M; Hietala M; Ringberg A; Ingvar C; Rose C; Jernström H
Cancer Causes Control; 2012 Aug; 23(8):1307-16. PubMed ID: 22695757
[TBL] [Abstract][Full Text] [Related]
3. Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey.
Tinari N; Fanizza C; Romero M; Gambale E; Moscetti L; Vaccaro A; Seminara P; Longo F; Gori S; Vici P; Gamucci T; Mauri M; Laudadio L; Nuzzo A; Fabbri MA; Fattoruso SI; Mazzilli L; Grassadonia A; Cianchetti E; Natoli C
Clin Breast Cancer; 2015 Apr; 15(2):e131-7. PubMed ID: 25454738
[TBL] [Abstract][Full Text] [Related]
4. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
5. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients.
Blackman SB; Lash TL; Fink AK; Ganz PA; Silliman RA
Cancer; 2002 Dec; 95(12):2465-72. PubMed ID: 12467058
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
9. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Adherence to oral endocrine therapy for breast cancer: a nursing perspective.
Miaskowski C; Shockney L; Chlebowski RT
Clin J Oncol Nurs; 2008 Apr; 12(2):213-21. PubMed ID: 18390458
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
Owusu C; Lash TL; Silliman RA
Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
[TBL] [Abstract][Full Text] [Related]
13. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
14. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
15. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
16. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
17. Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study.
Trédan O; Bajard A; Meunier A; Roux P; Fiorletta I; Gargi T; Bachelot T; Guastalla JP; Lallemand Y; Faure C; Pérol D; Bachmann P
Clin Nutr; 2010 Apr; 29(2):187-91. PubMed ID: 19713014
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
